China’s first GM rice gets US FDA approval
By Bai Tiantian,
Global Times
| 01. 22. 2018
A genetically modified (GM) rice product developed by a group of Chinese scientists has acquired the US Food and Drug Administration (FDA) approval, the first such Chinese product allowed to enter the US market.
However, neither China nor the US has approved mass cultivation of the rice amid low acceptance from the Chinese public for GM food.
Huahui No.1 rice, developed by the Huazhong Agricultural University, is genetically engineered to resist a wide range of insects, thus reducing the use of pesticides.
Lin Yongjun, a professor at Huazhong Agricultural University and one of the scientists that developed the rice, told the Global Times on Monday that Huahui No.1 could not be grown in China as "the country has not conducted regional trials nor provided guidelines to examine genetically engineered rice."
Lin said his team might consider growing Huahui No. 1 in Southeast Asian countries, "but our reach is limited and we hope the authorities can provide funding and legal support."
Lin's university received an email from the FDA on January 11 approving the rice.
The email, which was made public...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...